MedPath

Cariprazine

Generic Name
Cariprazine
Brand Names
Vraylar, Reagila
Drug Type
Small Molecule
Chemical Formula
C21H32Cl2N4O
CAS Number
839712-12-8
Unique Ingredient Identifier
F6RJL8B278
Background

Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT receptors and as an antagonist at serotonin 5-HT receptors. Cariprazine has been investigated in a variety of psychiatric disorders, including schizophrenia, bipolar disorders, and major depressive disorder. Cariprazine gained its first global approval in the US in September 2015 and was later approved by Health Canada in April 2022. It is currently used to treat schizophrenia, and manic or mixed episodes and depressive episodes associated with bipolar I disorder.

Indication

Cariprazine is indicated for the treatment of schizophrenia in adults to manage both positive and negative symptoms. It is also indicated to monotherapy for acute management of manic or mixed episodes associated with bipolar I disorder (bipolar mania) in adults, and acute management of depressive episodes associated with bipolar I disorder (bipolar depression) in adults.

Associated Conditions
Bipolar Disorder With Manic or Mixed Episodes, Depressive Episodes, Schizophrenia
Associated Therapies
-
Clinical Trials
Related News
globenewswire.com
·

Anxiety Disorders and Depression Treatment Market to Reach

The Anxiety Disorders and Depression Treatment Market was valued at USD 12.2 billion in 2023 and is projected to reach USD 16.65 billion by 2032, growing at a CAGR of 3.53%. This growth is driven by the rising prevalence of anxiety disorders and depression, advancements in pharmaceutical therapies, and increased awareness and destigmatization of mental health issues.
nortonrosefulbright.com
·

FTC's watchdog role in pharma mergers: Road bumps and the way forward

The FTC's 2023 revised merger guidelines impact pharmaceutical industries with stricter HHI and market share requirements, emphasizing direct evidence of market dominance and ecosystem competition. The FTC scrutinizes pharmaceutical mergers for market concentration, innovation, and entry barriers, with ongoing investigations into Novo Nordisk/Catalent and AbbVie/Cerevel mergers. The EC investigates Zoetis for potential abuse of dominance post-merger, and the FTC challenges fraudulent patents to prevent market monopolization. Pharmaceutical companies are increasingly merging with biotech firms to offset patent expirations and enhance product portfolios.
financialexpress.com
·

Bristol Myers gets USFDA nod for new type of schizophrenia drug

Bristol Myers Squibb receives FDA approval for Cobenfy, a new antipsychotic drug for schizophrenia, the first in decades. Cobenfy, also known as KarXT, lacks warnings about increased mortality in elderly patients and common side effects like weight gain and movement disorders. Bristol Myers expects $2.5 billion in U.S. sales by 2030 and plans to launch the drug at $1,850 a month. The approval is based on studies showing significant symptom reduction, targeting cholinergic receptors instead of dopamine. Cobenfy's side effects include vomiting and nausea, and it is not recommended for patients with urinary retention or severe kidney/liver disease.
yahoo.com
·

US FDA approves Bristol Myers' schizophrenia drug

The U.S. FDA approved Bristol Myers Squibb's schizophrenia drug, Cobenfy (KarXT), which reduces symptoms without common side effects, acquired through the $14 billion takeover of Karuna Therapeutics. Expected to generate $2.5 billion in U.S. sales by 2030, it targets cholinergic receptors, unlike traditional dopamine-targeting antipsychotics. Bristol plans to launch the drug in late October at $1,850 per month, with 80% of patients covered by Medicare and Medicaid.
mondaq.com
·

Antitrust And Competition Life Sciences Quarterly Update Q2 2024

2024 sees ongoing FTC scrutiny of life sciences transactions, including Novo's $16.5B Catalent acquisition and AbbVie's $8.7B Cerevel deal. The FTC challenges 'junk' patents in the FDA's Orange Book and releases an interim report on PBMs. The EU Commission opens its first abuse-of-dominance probe related to Zoetis shelving a veterinary therapy. Despite regulatory focus, deals in radiopharmaceuticals and metabolic diseases proceed without notable investigations.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy